Highlights Sino Biopharmaceutical Limited

Equities

1177

KYG8167W1380

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 01:38:03 20/05/2026 pm IST			5-day change	1st Jan Change
5.170 ^HKD	-1.34%		-10.55%	-16.34%

11/05	Global markets live: Alphabet, Cerebras, Compass, GSK, Rockwool…
11/05	Hong Kong Stocks Little Changed as U.S.-Iran Talks Remain Deadlocked; LDROBOT Gains on Debut	MT

Highlights

11/05	Sino Biopharmaceutical to Distribute GSK's Hepatitis B Drug in China	MT
07/05	Sino Biopharmaceutical says China CDE accepts new drug application for M701 CD3/Epcam bispecific antibody	RE
07/05	Sino Biopharmaceutical Limited Announces First Patient Enrollment in Phase III Registrational Clinical Trial of Cafelkibart CCR8 Monoclonal Antibody for Second-Line Gastric Cancer	CI
07/05	Sino Biopharmaceutical Limited Announces Acceptance Of New Drug Application For M701 Cd3/Epcam Bispecific Antibody	CI
06/05	Sino Biopharmaceutical's Culmerciclib capsule receives NMPA approval for first-line HR+/HER2- advanced breast cancer in China	RE
06/05	Sino Biopharmaceutical Limited Announces Approval of Culmerciclib Capsule CDK2/4/6 Inhibitor for First-Line Treatment of Breast Cancer	CI
20/04	Sino Biopharmaceutical says Benmelstobart, Anlotinib receive NMPA approval for advanced ASPS in China	RE
20/04	Sino Biopharmaceutical Limited Announces Approval of Benmelstobart in Combination with Anlotinib for Treatment of Alveolar Soft Part Sarcoma	CI
10/04	Sino Biopharmaceutical Limited Announces Completion of Enrollment of First Patient in Phase II Clinical Trial of Kylo-11 LPA SiRNA in the United States	CI
09/04	Sino Biopharmaceutical Receives US Regulatory Nod to Begin Trials of Anti Tumor Drug	MT
09/04	Sino Biopharmaceutical says application for clinical trial on TQB3205 "Pan-Kras inhibitor" approved by FDA	RE
27/03	Sino Biopharmaceutical Limited commences an Equity Buyback Plan for 1,876,071,723 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2025.	CI
26/03	Sino Biopharma's Profit Slips in 2025; Dividend Declared	MT
26/03	Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2025, Payable on 20 July 2026	CI
26/03	Sino Biopharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
17/03	Sino Biopharmaceutical says TRD221 receives NMPA clinical trial approval for osteoarthritis treatment	RE
12/03	Sino Biopharmaceutical reports positive results on phase III clinical study of TQB3454 IDH1 inhibitor	RE
11/03	Sino Biopharmaceutical says application for clinical trial on TQB3205 approved by NMPA	RE
02/03	Sino Biopharmaceutical's Blood Cancer Drug Approved in China	MT
02/03	Sino Biopharmaceutical receives NMPA approval for Rovadicitinib tablet	RE
02/03	Sino Biopharmaceutical Limited Announces Approval for Marketing	CI
16/02	Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing	RE
16/02	Sino Biopharmaceutical Wins China Nod for New Indication for Lung Cancer Drug	MT
16/02	National Medical Products Administration Approval for Marketing of Benmelstobart Injection for the Indication of Maintenance Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer	CI
10/02	Sino Biopharmaceutical Limited Announces Completion of Sub Project Enrollment in Phase III Clinical Trial of TQB2102 "Her2 Bispecific ADC" for HER2-Low Recurrent/Metastatic Breast Cancer	CI